Hemgenix has actually been presented ‘conditional authorisation’. Because of this the European Medicines Company made the decision that the main advantages of Hemgenix are larger than its pitfalls, but the company must offer additional evidence following authorisation.Authorities pointed out that the volume of patients expected to obtain etrana